How to explore Scott Alexander's work and his 1500+ blog posts? This unaffiliated fan website lets you sort and search through the whole codex. Enjoy!

See also Top Posts and All Tags.

Minutes:
Blog:
Year:
Show all filters
2 posts found
Feb 02, 2017
ssc
8 min 1,099 words 626 comments
Elizabeth Van Nostrand explains how the International Refugee Assistance Project's (IRAP) ground-level work with refugees enabled a rapid response to Trump's immigration ban, highlighting the importance of maintaining emergency response capacity. Longer summary
This guest post by Elizabeth VanNostrand discusses the importance of organizations like the International Refugee Assistance Project (IRAP) in responding to crises such as Trump's immigration ban. The author explains how IRAP's day-to-day work with individual refugee cases positioned them to respond quickly and effectively when the ban was implemented. The post highlights the value of maintaining capacity for emergency response, even when it may seem inefficient during non-crisis periods. It also emphasizes the importance of partnerships between organizations like IRAP and larger, more established groups like the ACLU. The author concludes by encouraging donations to IRAP or similar small charities doing ground-level work. Shorter summary
Jan 18, 2017
ssc
14 min 1,929 words 632 comments
Scott Alexander discusses potential Trump administration health-related appointments, focusing on FDA commissioner candidates Jim O'Neill and Balaji Srinivasan, and their potential to implement beneficial reforms. Longer summary
Scott Alexander discusses potential Trump administration picks for key health-related positions, particularly the FDA commissioner and NIH chief. He expresses excitement about the possibility of Jim O'Neill or Balaji Srinivasan being chosen for FDA commissioner, viewing them as principled libertarians who could implement beneficial reforms. Alexander outlines several policies these candidates might pursue, such as medical reciprocity with other countries and streamlining generic drug approvals. He also mentions John Ioannidis as a surprising potential pick for NIH chief, praising his work in improving medical research standards. The post concludes by noting that pharmaceutical industry stocks haven't moved much in response to these potential appointments. Shorter summary